These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 37567754

  • 1. Thinking beyond intravenous immunoglobulin for Kawasaki disease.
    Sage A, Jindal AK, Ramanan AV.
    Arch Dis Child; 2023 Oct; 108(10):781-782. PubMed ID: 37567754
    [No Abstract] [Full Text] [Related]

  • 2. Intravenous immunoglobulin plus corticosteroids prevent coronary artery abnormalities in Kawasaki disease.
    Brogan P, Levin M.
    Evid Based Med; 2013 Dec; 18(6):217-8. PubMed ID: 23564929
    [No Abstract] [Full Text] [Related]

  • 3. Immunoglobulin resistance in Kawasaki disease with chronic granulomatous disease.
    Tsuge M, Shigemitsu Y, Yano Y, Fujiwara M, Miyai T, Ueda K, Takata K, Moriwake T.
    Pediatr Int; 2012 Jun; 54(3):e32-4. PubMed ID: 22631588
    [No Abstract] [Full Text] [Related]

  • 4. [Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease].
    Kobayashi T, Inoue Y, Morikawa A.
    Nihon Rinsho; 2008 Feb; 66(2):332-7. PubMed ID: 18260333
    [Abstract] [Full Text] [Related]

  • 5. [Immunoglobulin in suspected Kawasaki disease].
    García Soblechero E, Gómez Santos E, Domínguez Quintero ML, González Vila L.
    An Pediatr (Barc); 2010 Sep; 73(3):151-2. PubMed ID: 20605119
    [No Abstract] [Full Text] [Related]

  • 6. [Tumor necrosis factor-α inhibitors in the treatment of intravenous immunoglobulin non-responders of Kawasaki disease].
    Xiong Y, Du ZD.
    Zhonghua Er Ke Za Zhi; 2020 Mar 02; 58(3):248-251. PubMed ID: 32135603
    [Abstract] [Full Text] [Related]

  • 7. Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease.
    Nakagawa M, Watanabe N, Okuno M, Kondo M, Okagawa H, Taga T.
    Am J Hematol; 2000 Mar 02; 63(3):160-1. PubMed ID: 10679809
    [No Abstract] [Full Text] [Related]

  • 8. Resistance to intravenous immunoglobulin (IVIG) in Kawasaki disease: no influence of different IVIG lot utilisation.
    Pagnini I, Marino A, Simonini G, Cimaz R.
    Clin Exp Rheumatol; 2012 Mar 02; 30(1 Suppl 70):S170. PubMed ID: 22410254
    [No Abstract] [Full Text] [Related]

  • 9. A meta-analysis of re-treatment for intravenous immunoglobulin-resistant Kawasaki disease.
    Chandelia S.
    Cardiol Young; 2015 Aug 02; 25(6):1228. PubMed ID: 25904322
    [No Abstract] [Full Text] [Related]

  • 10. Early intravenous gamma globulin retreatment for refractory Kawasaki disease.
    Chiyonobu T, Yoshihara T, Mori K, Ishida H, Nishimura Y, Yamamoto Y, Kamiya Y, Kasubuchi Y.
    Clin Pediatr (Phila); 2003 Apr 02; 42(3):269-72. PubMed ID: 12739926
    [No Abstract] [Full Text] [Related]

  • 11. BCL2L11 Is Associated With Kawasaki Disease in Intravenous Immunoglobulin Responder Patients.
    Kwon YC, Kim JJ, Yun SW, Yu JJ, Yoon KL, Lee KY, Kil HR, Kim GB, Han MK, Song MS, Lee HD, Ha KS, Sohn S, Hong YM, Jang GY, Lee JK, Korean Kawasaki Disease Genetics Consortium.
    Circ Genom Precis Med; 2018 Feb 02; 11(2):e002020. PubMed ID: 29453247
    [No Abstract] [Full Text] [Related]

  • 12. Late-onset and long-term systemic dyshidrotic eczema after intravenous immunoglobulin treatment for Kawasaki disease.
    Yokoyama K, Yoshida A.
    BMJ Case Rep; 2019 Mar 21; 12(3):. PubMed ID: 30902846
    [No Abstract] [Full Text] [Related]

  • 13. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study.
    Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, Baker A, Fulton DR, Sundel RP, Newburger JW.
    J Pediatr; 2011 Apr 21; 158(4):644-649.e1. PubMed ID: 21129756
    [Abstract] [Full Text] [Related]

  • 14. [Intravenous immunoglobulin-resistant Kawasaki disease with hemophagocytosis].
    Servel AC, Vincenti M, Darras JP, Lalande M, Rodière M, Filleron A.
    Arch Pediatr; 2012 Jul 21; 19(7):741-4. PubMed ID: 22652521
    [Abstract] [Full Text] [Related]

  • 15. Third-line therapies in patients with Kawasaki disease refractory to first- and second-line intravenous immunoglobulin therapy.
    Furuta T, Yasudo H, Okada S, Ohnishi Y, Kawakami-Miyake A, Suzuki Y, Ohga S, Hasegawa S.
    World J Pediatr; 2022 Nov 21; 18(11):781-785. PubMed ID: 35976528
    [No Abstract] [Full Text] [Related]

  • 16. Transient Deformation of Neutrophils in Kawasaki Disease.
    Koike Y, Yanagisawa R, Ogiso Y, Cho Y, Minami K, Takeuchi K, Sakashita K, Higuchi T.
    J Pediatr; 2016 Jun 21; 173():238-241.e1. PubMed ID: 27039225
    [Abstract] [Full Text] [Related]

  • 17. [Kawasaki syndrome in adults: treatment with polyvalent intravenous immunoglobulins].
    Pavese P, Brion JP, Meusnier T, Stahl JP.
    Ann Med Interne (Paris); 1997 Jun 21; 148(3):287-8. PubMed ID: 9255342
    [No Abstract] [Full Text] [Related]

  • 18. Treatment Options for Resistant Kawasaki Disease.
    Phuong LK, Curtis N, Gowdie P, Akikusa J, Burgner D.
    Paediatr Drugs; 2018 Feb 21; 20(1):59-80. PubMed ID: 29101553
    [Abstract] [Full Text] [Related]

  • 19. Recurrent Kawasaki disease.
    Balasubramanian S, Ganesh R.
    Indian J Pediatr; 2009 Aug 21; 76(8):848-9. PubMed ID: 19475343
    [Abstract] [Full Text] [Related]

  • 20. Prediction of intravenous immunoglobulin-resistant Kawasaki disease: a research hotspot.
    Xu B, Zhang Q, Du J, Shiraishi I, Jin H.
    Sci Bull (Beijing); 2023 Jan 30; 68(2):121-124. PubMed ID: 36681588
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.